Search - tctmd.com

Displaying 181 - 200 of 1207

Sort: Relevancy | Date

BP Reduction With Renal Denervation Still Evident a Decade On

News Daily News

BP Reduction With Renal Denervation Still Evident a Decade On

Michael O'Riordan

January 31, 2023

Angioedema Risk No Higher With ARNI Than With ACE Inhibitors, ARBs

News Daily News

Angioedema Risk No Higher With ARNI Than With ACE Inhibitors, ARBs

January 23, 2023

RECORD4 Trial of Rivaroxaban, Published in 2009, Still Turning Heads

News Daily News

RECORD4 Trial of Rivaroxaban, Published in 2009, Still Turning Heads

January 19, 2023

Medical Devices Cleared on Faulty Predicates More Likely to be Recalled

News Daily News

Medical Devices Cleared on Faulty Predicates More Likely to be Recalled

Michael O'Riordan

January 17, 2023

Semaglutide Effective for Weight Loss in Adolescents: STEP TEENS

News Daily News

Semaglutide Effective for Weight Loss in Adolescents: STEP TEENS

Michael O'Riordan

December 30, 2022

Reduction in BP Drives Treatment Preference for Hypertensive Patients

News Daily News

Reduction in BP Drives Treatment Preference for Hypertensive Patients

Michael O'Riordan

December 20, 2022

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

News Daily News

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

Michael O'Riordan

December 14, 2022

Impella RP Mortality Rate No Longer a Concern, FDA Says

News Daily News

Impella RP Mortality Rate No Longer a Concern, FDA Says

December 05, 2022

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

News Conference News VIVA 2022

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

November 03, 2022

More Endpoints, More Problems: FDA Offers Advice for Multi-endpoint Trials

News Daily News

More Endpoints, More Problems: FDA Offers Advice for Multi-endpoint Trials

Michael O'Riordan

October 28, 2022

US Claims Data Point to Better Survival With Impella vs IABP in High-Risk PCI

News Daily News

US Claims Data Point to Better Survival With Impella vs IABP in High-Risk PCI

October 20, 2022

Most Patient-Reported Outcome Measures in CVD Fall Short

News Daily News

Most Patient-Reported Outcome Measures in CVD Fall Short

September 23, 2022

Strengths and Limitations of Patient Reported Outcomes as Major Endpoints in "Modern Era" CV Trials

Presentation TCT 2022

Strengths and Limitations of Patient Reported Outcomes as Major Endpoints in "Modern Era" CV Trials

Presenter: Alexander Iribarne

September 19, 2022

Amulet, Watchman 2.5 LAAO Devices Provide Comparable 3-Year Outcomes

News Conference News TCT 2022

Amulet, Watchman 2.5 LAAO Devices Provide Comparable 3-Year Outcomes

September 18, 2022

FDA Approves Pascal TEER Device for Degenerative MR

News Daily News

FDA Approves Pascal TEER Device for Degenerative MR

September 15, 2022

Steep Rise in PVAD Support for Protected PCI: Medicare Data

News Daily News

Steep Rise in PVAD Support for Protected PCI: Medicare Data

August 19, 2022

FDA: Class I Recall of Cobalt and Crome ICDs and CRT-Ds Due to Reduced-Energy Shock

News Daily News

FDA: Class I Recall of Cobalt and Crome ICDs and CRT-Ds Due to Reduced-Energy Shock

August 19, 2022

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

News Features

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Michael O'Riordan

August 15, 2022

RADIANCE II Top-Line Results Promising for Ultrasound Renal Denervation

News Daily News

RADIANCE II Top-Line Results Promising for Ultrasound Renal Denervation

July 26, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.